Monarch Medical Technologies announced that it appointed industry veteran Raymie McFarland as its new president & CEO.
As McFarland takes over day-to-day management, Brian Duffy and Christophe Mallard, two of the Charlotte, N.C.-based diabetes technology company’s board members, will relinquish their respective roles as interim CEO and interim president.
McFarland spent the previous nine years with Glytec, having most recently served as the company’s chief innovation & outcomes officer. Before Glytec, McFarland worked at Sanofi in diabetes care.
“We are thrilled to welcome Raymie to the Monarch family,” Duffy said in a news release. “He is, as many people will attest, a one-of-a-kind talent. His in-depth knowledge of diabetes and, more specifically, of glycemic management and insulin therapies, is extraordinary.”
“Raymie’s track record of success in cultivating customer relationships, building high-performing teams, engaging key opinion leaders and generating revenue is unimpeachable,” Mallard added. “He has a keen ability to articulate the benefits of innovative tools, technologies and processes to clinicians, administrators and senior executives alike. He is also highly experienced in conducting scientific research and measuring both clinical efficacy and financial ROI.”
